Seelos Therapeutics, Inc.

Equities

SEEL

US81577F2083

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.291 ^USD	+1.89%		-13.00%	-79.06%

Mar. 19	Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	MT
Mar. 19	Seelos Therapeutics' ALS treatment fails in mid-stage study	RE

Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 06, 2024 at 04:51 pm EST

Seelos Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 2.2 million. Net loss was USD 37.88 million compared to USD 73.53 million a year ago.

Basic loss per share from continuing operations was USD 7.73 compared to USD 20.74 a year ago. Diluted loss per share from continuing operations was USD 7.73 compared to USD 20.74 a year ago.

Latest news about Seelos Therapeutics, Inc.

Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	Mar. 19	MT
Seelos Therapeutics' ALS treatment fails in mid-stage study	Mar. 19	RE
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)	Mar. 19	CI
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	Mar. 04	MT
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	Mar. 03	MT
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement	Jan. 26	MT
Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002	Jan. 22	CI
Certain Warrants of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	Jan. 12	CI
Certain Stock Options of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	Jan. 12	CI
Certain Common Stock of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	Jan. 12	CI
Sector Update: Health Care Stocks Gain Premarket Tuesday	Dec. 19	MT
Seelos Therapeutics Files $250 Million Mixed Shelf	Dec. 19	MT
Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from S&P Global BMI Index	Dec. 18	CI
Seelos Therapeutics Insider Bought Shares Worth $100,223, According to a Recent SEC Filing	Dec. 01	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	Nov. 29	MT
Sector Update: Health Care	Nov. 29	MT
Top Midday Decliners	Nov. 29	MT
Top Premarket Decliners	Nov. 29	MT
Seelos Therapeutics Prices Common Stock Offering	Nov. 29	MT
Seelos Therapeutics Commences Common Stock Offering	Nov. 28	MT
Seelos Therapeutics, Inc. Announces the Selection of SLS-002 (intranasal Racemic Ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder	Nov. 27	CI
Top Decliners	Nov. 24	MT
Sector Update: Health Care Stocks Higher Friday Afternoon	Nov. 24	MT
Seelos Therapeutics Approves 1-for-30 Reverse Split of Common Stock; Shares Fall	Nov. 24	MT

Chart Seelos Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

Sector

Biotechnology & Medical Research

Calendar

2024-08-01 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
SEELOS THERAPEUTICS, INC.	-79.06%	3.98M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs